![]() |
UMIN-CTR Clinical Trial |
|
![]() |
![]() |
![]() |
![]() |
Name: | UMIN ID: |
Recruitment status | Completed |
Unique ID issued by UMIN | UMIN000018446 |
Receipt No. | R000021358 |
Scientific Title | A study for safety evaluation of 12-weeks consumption of the drink containing indigestible dextrin. |
Date of disclosure of the study information | 2015/07/29 |
Last modified on | 2015/12/24 |
Basic information | ||
Public title | A study for safety evaluation of 12-weeks consumption of the drink containing indigestible dextrin. | |
Acronym | A study for safety evaluation of 12-weeks consumption of the drink containing indigestible dextrin. | |
Scientific Title | A study for safety evaluation of 12-weeks consumption of the drink containing indigestible dextrin. | |
Scientific Title:Acronym | A study for safety evaluation of 12-weeks consumption of the drink containing indigestible dextrin. | |
Region |
|
Condition | |||
Condition | Healthy adult | ||
Classification by specialty |
|
||
Classification by malignancy | Others | ||
Genomic information | NO |
Objectives | |
Narrative objectives1 | Safety evaluation of 12-weeks consumption of the drink which contain indigestible dextrin. |
Basic objectives2 | Safety |
Basic objectives -Others | |
Trial characteristics_1 | |
Trial characteristics_2 | |
Developmental phase |
Assessment | |
Primary outcomes | The incidence of side effects |
Key secondary outcomes | Blood test
Urine test Blood pressure/pulsation Weight/body mass index Medical interview |
Base | |
Study type | Interventional |
Study design | |
Basic design | Parallel |
Randomization | Randomized |
Randomization unit | |
Blinding | Double blind -all involved are blinded |
Control | Placebo |
Stratification | |
Dynamic allocation | |
Institution consideration | |
Blocking | |
Concealment |
Intervention | ||
No. of arms | 2 | |
Purpose of intervention | Treatment | |
Type of intervention |
|
|
Interventions/Control_1 | Drink which is contain indigestible dextrin 5g as dietary fiber. Intake 350mL/day, 12 weeks. | |
Interventions/Control_2 | Drink which is not contain indigestible dextrin. Intake 350mL/day, 12 weeks. | |
Interventions/Control_3 | ||
Interventions/Control_4 | ||
Interventions/Control_5 | ||
Interventions/Control_6 | ||
Interventions/Control_7 | ||
Interventions/Control_8 | ||
Interventions/Control_9 | ||
Interventions/Control_10 |
Eligibility | ||||
Age-lower limit |
|
|||
Age-upper limit |
|
|||
Gender | Male and Female | |||
Key inclusion criteria | (1)Subjects giving written informed consent
(2)Healthy males and females aged 20 to 64 years old. (3) Subjects who falls under any of the following criteria. A. Fasting blood glucose levels at preliminary test are less than 100mg/dL. (around 18 subjects) B. Fasting blood glucose levels at preliminary test are between more than 100mg/dL and less than 126mg/dL. (around 12 subjects) |
|||
Key exclusion criteria | (1)Subjects who are given continuous treatment by taking medicines.
(2) Subjects who constantly use oral medicines, functional foods and/or supplements having a possibility of affecting test results. (3)Subjects who have previous and/or current medical history of serious disease (e.g., heart, liver, kidney, digestive organ). (4) Females who are pregnant or lactating, and females who could become pregnant or lactating during test period. (5)Subjects who excessive alcohol intake. (6) Subjects who have extremely irregular dining habits, and subjects who have midnight work or irregular shift work. (7)Subjects who have previous medical history of drug and/or food allergy. (8) Subjects who are participating the other clinical tests. Subjects who participated within 4-weeks prior to the current study and/or who plan to participate the other clinical tests. (9)Subjects who donated over 200mL blood and/or blood components within the last one month to the current study. (10) Subjects who donated over 400mL blood and/or blood components within the last three month to the current study. (11) Females who donated over 400mL blood and/or blood components within the last four month to the current study. (12) Males who will be collected over 1200mL blood and/or blood components, when the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study. (13) Females who will be collected over 800mL blood and/or blood components when, the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study. (14)Others who have been determined ineligible by principal investigator or sub-investigator. |
|||
Target sample size | 30 |
Research contact person | |||||||
Name of lead principal investigator |
|
||||||
Organization | CPCC Company Limited | ||||||
Division name | Clinical Research Planning Department | ||||||
Zip code | |||||||
Address | 4F Chushin Build. 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047 Japan | ||||||
TEL | 03-5297-3112 | ||||||
k.s@cpcc.co.jp |
Public contact | |||||||
Name of contact person |
|
||||||
Organization | CPCC Company Limited | ||||||
Division name | Plan Sales Department | ||||||
Zip code | |||||||
Address | 4F Chushin Build. 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047 Japan | ||||||
TEL | 03-5297-3112 | ||||||
Homepage URL | |||||||
m.i@cpcc.co.jp |
Sponsor | |
Institute | CPCC Company Limited |
Institute | |
Department |
Funding Source | |
Organization | ASAHI BREWERIES, LTD. |
Organization | |
Division | |
Category of Funding Organization | Profit organization |
Nationality of Funding Organization |
Other related organizations | |
Co-sponsor | |
Name of secondary funder(s) |
IRB Contact (For public release) | |
Organization | |
Address | |
Tel | |
Secondary IDs | |
Secondary IDs | NO |
Study ID_1 | |
Org. issuing International ID_1 | |
Study ID_2 | |
Org. issuing International ID_2 | |
IND to MHLW |
Institutions | |
Institutions |
Other administrative information | |||||||
Date of disclosure of the study information |
|
Related information | |
URL releasing protocol | |
Publication of results | Unpublished |
Result | |
URL related to results and publications | |
Number of participants that the trial has enrolled | |
Results | |
Results date posted | |
Results Delayed | |
Results Delay Reason | |
Date of the first journal publication of results | |
Baseline Characteristics | |
Participant flow | |
Adverse events | |
Outcome measures | |
Plan to share IPD | |
IPD sharing Plan description |
Progress | |||||||
Recruitment status | Completed | ||||||
Date of protocol fixation |
|
||||||
Date of IRB | |||||||
Anticipated trial start date |
|
||||||
Last follow-up date | |||||||
Date of closure to data entry | |||||||
Date trial data considered complete | |||||||
Date analysis concluded |
Other | |
Other related information |
Management information | |||||||
Registered date |
|
||||||
Last modified on |
|
Link to view the page | |
URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021358 |
Research Plan | |
Registered date | File name |
Research case data specifications | |
Registered date | File name |
Research case data | |
Registered date | File name |